Abstract
Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Current Drug Delivery
Title:Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Volume: 10 Issue: 1
Author(s): Jean-Luc Balligand
Affiliation:
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Abstract: Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Export Options
About this article
Cite this article as:
Balligand Jean-Luc, Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor, Current Drug Delivery 2013; 10 (1) . https://dx.doi.org/10.2174/1567201811310010011
DOI https://dx.doi.org/10.2174/1567201811310010011 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cord Blood as Diagnostic Window for Preeclampsia
Recent Patents on Biomarkers Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Target Peptide Recognition by S100P Protein and Role of Central Linker Region and Dimer Interface
Protein & Peptide Letters Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Methods to Evaluate the Inhibition of TTR Fibrillogenesis Induced by Small Ligands
Current Medicinal Chemistry microRNAs in Cardiovascular Disease: Small Molecules but Big Roles
Current Topics in Medicinal Chemistry Recent Patents and Advances in the Next-Generation Sequencing Technologies
Recent Patents on Biomedical Engineering (Discontinued) Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters